SCHEMBL26092955

SCHEMBL26092955

O=C1C2CN(Cc3ccsc3)CCN2C(=O)CN1Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ KMT2A Q03164 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ITGA4 P13612 1/20 0.39
▸ ITGB7 P26010 1/20 0.39
▸ OPRM1 P35372 1/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ OPRK1 P41145 1/20 0.39
▸ OPRL1 P41146 1/20 0.39
▸ DRD2 P14416 4/20 0.38
▸ DRD4 P21917 4/20 0.38
▸ TACR1 P25103 2/20 0.38
▸ HTR1A P08908 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30337582 0.90 SMN1; SMN2 (0.45) SIGMAR1KMT2ASMN1; SMN2TACR1HTR1A
SCHEMBL30337246 0.84 ENPP2 (0.47) KMT2ASMN1; SMN2DRD2DRD4TACR1
SCHEMBL24145803 0.83 ENPP2 (0.48) ALDH1A1DRD2HTR1A
SCHEMBL30336976 0.80 KMT2A (0.55) SIGMAR1KMT2ADRD4HTR1AMEN1
SCHEMBL30337155 0.79 TACR1 (0.43) KMT2ASMN1; SMN2ALDH1A1KDM4ETACR1
SCHEMBL30337300 0.77 HTR1A (0.45) LMNAKMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL30337148 0.76 FAAH (0.46) —
SCHEMBL30337505 0.76 ALDH1A1 (0.46) KMT2ASMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL30337060 0.76 KMT2A (0.49) KMT2ADRD4HTR1AMEN1
SCHEMBL24938893 0.75 CYP19A1 (0.43) KMT2AHTR1AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101562-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME HOLOSMEDIC (KR) 2024-03-28 — — US disclosed
EP-4174068-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME Holosmedic (KR) 2023-05-03 — — EP disclosed
CN-115916206-A Novel compound and pharmaceutical composition for preventing or treating resistant cancer comprising same 治愈医药社株式会社 2023-04-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101562-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME SLC11A2, ABCC1, TSG101 SIGMAR1 3406/4885LMNA 2799/4885KMT2A 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback